"Pioneering Fully Automated AI Customer Acquisition"
TORONTO, ON / ACCESSWIRE / August 8, 2024 / Bionoid Pharma, Inc. ("BINP") (OTC PINK:BINP) announces the signing of a definitive agreement with Stronghold Media Group Corp. ("Stronghold") to acquire the intellectual property rights of AI Maverick Intel, a cutting-edge technology set to revolutionize customer acquisition by enabling companies to find, engage, nurture, and acquire their ideal audiences at high velocity and automated scale.
Revolutionizing Audience Engagement with AI Maverick Intel
AI Maverick Intel is a game-changer in tech acquisitions. Utilizing state-of-the-art AI technology, it redefines how companies identify, reach, and engage their target audiences. The platform's advanced automation capabilities empower businesses to achieve efficient customer acquisition with minimal human involvement, maximizing productivity and precision at every touchpoint.
"We are very excited about this new chapter for Bionoid Pharma," said Wayne Cockburn, Interim CEO of Bionoid Pharma. "By harnessing the transformative power of AI Maverick Intel, we are poised to redefine audience engagement. This acquisition propels us towards a future where companies can seamlessly acquire customers with less data and communication fragmentation. It underscores our unwavering commitment to innovation, sustainable growth, and establishing Bionoid as a leader in AI-driven execution."
A Strategic Divestiture to Focus on Digital Transformation
In alignment with this new strategic direction, Bionoid Pharma has sold its 100% stake in Medical Magnetics Inc. (formerly BIOflex Medical Magnetics Inc.) to Lily Zablotsky for nominal consideration. This move is part of Bionoid's broader strategy of streamlining operations and leveraging AI and automation to drive future growth and innovation.
About AI Maverick Intel
AI Maverick Intel is at the forefront of digital transformation in audience engagement. By leveraging cutting-edge AI and machine learning algorithms, this platform redefines how companies connect and scale communications with their target audiences. Its sophisticated automation capabilities ensure highly efficient and impactful marketing campaigns, driving seamless and automated customer acquisition.
For further information, contact:
Wayne Cockburn, Interim CEO
Phone: (905) 505-0770
[email protected]
SOURCE: Bionoid Pharma, Inc.
View the original press release on accesswire.com
